Phase 1b trial launched of inhaled nintedanib for pulmonary fibrosis

Phase 1b trial launched of inhaled nintedanib for pulmonary fibrosis

Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate for pulmonary fibrosis (PF), in adult healthy volunteers. The placebo-controlled trial of inhaled nintedanib will assess its safety, tolerability, and pharmacological profile when given at single or multiple ascending doses. Its main goal…

US patent covers brilaroxazine in treating IPF, like diseases

Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…

Partnership will bring Brainomix AI-powered tool to US centers

Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…

The high costs of living with IPF and other rare diseases

Living with a rare disease is expensive. While I agree with the cliches that “money can’t buy happiness” and “time is more valuable than money,” the limited financial aid available to patients stresses me out. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I wasn’t thinking…

Enrollment complete for Phase 2a trial of IPF treatment BBT-877

Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…